Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Urology, University of Muenster Medical Center, Muenster, Germany.
Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
J Urol. 2014 Jan;191(1):28-34. doi: 10.1016/j.juro.2013.07.012. Epub 2013 Jul 16.
We determined the association of the proliferation marker Ki-67 with pathological parameters and oncologic outcomes in patients with high grade upper tract urothelial carcinoma.
Immunohistochemical staining for Ki-67 was done prospectively in 101 consecutive patients undergoing radical nephroureterectomy/ureterectomy for high grade upper tract urothelial carcinoma. Data were compared based on Ki-67 status (normal vs over expressed). Survival was assessed by the Kaplan-Meier method. Cox regression analysis was done to identify independent predictors of time dependent outcomes.
Median patient age was 70.0 years and median followup was 22.0 months (range 1 to 77). Overall, 30.2% of the population experienced recurrence and 24.8% died of upper tract urothelial carcinoma. Organ confined disease (T2 or less and lymph node negative), lymphovascular invasion and sessile architecture were present in 56.3%, 33.3% and 20.8% of patients, respectively. Ki-67 was over expressed in 73.3% of patients and associated with adverse pathological features. Patients with over expressed Ki-67 had significantly worse recurrence-free survival (43.2 vs 69.0 months, p = 0.006) and cancer specific survival (48.9 vs 68.9 months, p = 0.031) than patients with normal Ki-67. Patients with nonmetastatic disease similarly had worse recurrence-free survival (40.7 vs 71.8 months, p = 0.003) and cancer specific survival (41 months vs not attained, p = 0.008) for over expressed vs normal Ki-67. After adjusting for the effects of organ vs nonorgan confined disease Ki-67 over expression was an independent predictor of recurrence-free survival in the total cohort (HR 4.3, p = 0.05) and in patients with nonmetastatic disease (HR 8.5, p = 0.038).
Ki-67 over expression was associated with adverse pathological features in cases of upper tract urothelial carcinoma. It was also an independent predictor of recurrence-free survival in patients with high grade upper tract urothelial carcinoma.
我们旨在确定增殖标志物 Ki-67 与高级别上尿路上皮癌患者的病理参数和肿瘤学结局的关系。
前瞻性地对 101 例接受根治性肾输尿管切除术/输尿管切除术治疗高级别上尿路上皮癌的连续患者进行 Ki-67 免疫组织化学染色。根据 Ki-67 状态(正常与过度表达)对数据进行比较。通过 Kaplan-Meier 方法评估生存情况。使用 Cox 回归分析确定与时间相关结局相关的独立预测因子。
患者中位年龄为 70.0 岁,中位随访时间为 22.0 个月(范围 1 至 77 个月)。总体而言,30.2%的患者出现复发,24.8%的患者死于上尿路上皮癌。器官局限性疾病(T2 或以下且淋巴结阴性)、血管淋巴管侵犯和贴壁结构分别存在于 56.3%、33.3%和 20.8%的患者中。73.3%的患者 Ki-67 过度表达,且与不良病理特征相关。Ki-67 过度表达的患者无复发生存率(43.2 与 69.0 个月,p=0.006)和癌症特异性生存率(48.9 与 68.9 个月,p=0.031)明显低于 Ki-67 正常的患者。同样,非转移性疾病患者 Ki-67 过度表达的无复发生存率(40.7 与 71.8 个月,p=0.003)和癌症特异性生存率(41 个月与未达到,p=0.008)也较差。在调整器官与非器官局限性疾病的影响后,Ki-67 过度表达是总队列无复发生存率的独立预测因子(HR 4.3,p=0.05)和非转移性疾病患者的独立预测因子(HR 8.5,p=0.038)。
Ki-67 过度表达与上尿路上皮癌的不良病理特征相关。它也是高级别上尿路上皮癌患者无复发生存率的独立预测因子。